MY148518A - Crystalline parecoxib sodium - Google Patents

Crystalline parecoxib sodium

Info

Publication number
MY148518A
MY148518A MYPI20030900A MYPI20030900A MY148518A MY 148518 A MY148518 A MY 148518A MY PI20030900 A MYPI20030900 A MY PI20030900A MY PI20030900 A MYPI20030900 A MY PI20030900A MY 148518 A MY148518 A MY 148518A
Authority
MY
Malaysia
Prior art keywords
parecoxib sodium
anhydrous
nonsolvated
drug substance
crystal forms
Prior art date
Application number
MYPI20030900A
Other languages
English (en)
Inventor
Ahmad Y Sheikh
Thomas B Borchardt
Leonard J Ferro
Gerald D Danzer
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MY148518A publication Critical patent/MY148518A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D457/00Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06Lysergic acid amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MYPI20030900A 2002-03-15 2003-03-14 Crystalline parecoxib sodium MY148518A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36456702P 2002-03-15 2002-03-15
US41798702P 2002-10-11 2002-10-11

Publications (1)

Publication Number Publication Date
MY148518A true MY148518A (en) 2013-04-30

Family

ID=28045416

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20030900A MY148518A (en) 2002-03-15 2003-03-14 Crystalline parecoxib sodium

Country Status (18)

Country Link
US (1) US20030232871A1 (enExample)
EP (1) EP1485362A1 (enExample)
JP (1) JP2005529084A (enExample)
KR (1) KR100763045B1 (enExample)
CN (1) CN1642926A (enExample)
AR (1) AR038985A1 (enExample)
AU (1) AU2003220180A1 (enExample)
BR (1) BR0308431A (enExample)
CA (1) CA2478500A1 (enExample)
CO (1) CO5631437A2 (enExample)
IL (1) IL163780A0 (enExample)
MX (1) MXPA04008932A (enExample)
MY (1) MY148518A (enExample)
NZ (1) NZ535951A (enExample)
PL (1) PL372880A1 (enExample)
RU (1) RU2300529C2 (enExample)
TW (1) TW200400949A (enExample)
WO (1) WO2003078408A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003238669A1 (en) * 2003-04-04 2004-10-25 Hetero Drugs Limited Novel crystalline forms of parecoxib sodium
US7268109B2 (en) 2003-10-02 2007-09-11 Elan Pharmaceuticals, Inc. Method for reducing pain
WO2005065684A1 (en) * 2003-12-24 2005-07-21 Pharmacia Corporation Metal salts of parecoxib as prodrugs of the cox-2 inhibitor valdecoxib for the treatment of inflammation, pain and/or fever
ITMI20040019A1 (it) * 2004-01-12 2004-04-12 Univ Bari Derivati isossazolici e loro impiego come inibitori della ciclossigenasi
US7796785B2 (en) * 2005-03-03 2010-09-14 Fujifilm Corporation Image extracting apparatus, image extracting method, and image extracting program
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
US7989450B2 (en) 2008-01-11 2011-08-02 Universita' Degli Studi Di Bari Functionalized diarylisoxazoles inhibitors of ciclooxygenase
GB0919757D0 (en) * 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8299295B2 (en) 2009-10-15 2012-10-30 Johnson Matthey Public Limited Company Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN106692079A (zh) * 2016-12-26 2017-05-24 上药东英(江苏)药业有限公司 一种帕瑞昔布钠长效冻干粉针制剂
CN106580893A (zh) * 2016-12-26 2017-04-26 上药东英(江苏)药业有限公司 一种帕瑞昔布钠冻干粉针制剂
CN117003769B (zh) * 2023-07-11 2024-11-22 中国科学院宁波材料技术与工程研究所 氯诺昔康复合物、氯诺昔康-小檗碱共晶及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT892791E (pt) * 1996-04-12 2003-06-30 Searle & Co N-¬¬4-(5-metil-3-fenilisoxazol-4-il|fenil|sulfonil-propilamida e seu sal de sodio como pro-farmacos de inibidores de cox-2
KR20000049138A (ko) * 1996-10-15 2000-07-25 윌리암스 로저 에이 신생물의 치료 및 예방에의 시클로옥시게나제-2 저해제의 사용방법
PE20021017A1 (es) * 2001-04-03 2002-11-24 Pharmacia Corp Composicion parenteral reconstituible
KR20040085135A (ko) * 2001-10-02 2004-10-07 파마시아 코포레이션 벤젠설포닐 화합물의 제조 방법

Also Published As

Publication number Publication date
IL163780A0 (en) 2005-12-18
CO5631437A2 (es) 2006-04-28
JP2005529084A (ja) 2005-09-29
KR20040095288A (ko) 2004-11-12
WO2003078408A1 (en) 2003-09-25
RU2300529C2 (ru) 2007-06-10
AR038985A1 (es) 2005-02-02
CA2478500A1 (en) 2003-09-25
KR100763045B1 (ko) 2007-10-04
MXPA04008932A (es) 2004-11-26
RU2004127585A (ru) 2005-04-10
PL372880A1 (en) 2005-08-08
CN1642926A (zh) 2005-07-20
AU2003220180A1 (en) 2003-09-29
NZ535951A (en) 2006-02-24
TW200400949A (en) 2004-01-16
EP1485362A1 (en) 2004-12-15
US20030232871A1 (en) 2003-12-18
BR0308431A (pt) 2005-01-18

Similar Documents

Publication Publication Date Title
MY148518A (en) Crystalline parecoxib sodium
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
MY136926A (en) Glucokinase activators
IL198783A0 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
TW200626558A (en) Indazolone derivatives
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
UA94052C2 (uk) Похідні піридазину
NO20053498L (no) Derivater av aryl-quinaolin/aryl-2-amino-fenylmetanon som fremmer frigivelse av paratyroidhormon
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
GB2352972A (en) Use of dexmedetomidine for icu sedation
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MY135646A (en) Indolyl derivatives
MY142648A (en) Stabilized freeze-dried formulation for cephalosporin derivatives
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
MX2007003105A (es) Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i.
IL141232A0 (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
AU2566101A (en) Compounds and methods for the treatment of pain
WO2001085144A3 (en) Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
AU8186701A (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents
YU20902A (sh) Primena karbinola supstituisanih sa 2-imidazolilom za izradu medikamenta za lečenje ili profilaksu oboljenja izazvanih ishemičkim stanjima
JPS5665079A (en) Stabilization of ground
TH63282A (th) พาเรโคซิบโซเดียมที่เป็นผลึก
TW200744616A (en) Drugs for treating cerebral infarction